this from the Financial Times piece today:
However, analysts and physicians voiced concerns over the drug’s safety, with a quarter of patients on the highest dose discontinuing treatment due to adverse effects, including swelling on the brain.
ignore analysts on both sides, and especially ignore price targets. they are for the herd only
with maybe 10-15 percent annual growth; like it as potential takeout candidate as industry consolidates. The big guys are coming in now, like Hewlett Packard etc.